• Level-Setting on Law 25
• Second round of obligations being enforced in 2023
• Considerations and best practices to make for preparedness and compliance
• Common questions asked and answered

In a world where sharing a published article or research study can be as easy as a mouse click, organizations struggle to manage their risks around copyright infringement while also enabling collaboration and knowledge sharing. Each publisher has its own restrictions on reuse, and risk managers face the challenge of complying with a wide variety of subscription terms and conditions. In addition, as more organizations cut back or eliminate their internal libraries, employees lack guidance on how to share and distribute digital content while remaining within the bounds of copyright laws. By strategic licensing of content—in addition to their traditional subscriptions—pharma organizations can reduce risk and administrative costs and collaborate strategically with others both within and outside the enterprise. Key takeaways include:

• How licensing content can increase its value to the organization
• Why protecting the organization from the risk of copyright infringement matters in the digital age
• How copyright licenses benefit the enterprise in streamlined access and risk mitigation

Though output metrics are undeniably important when it comes to monitoring and measuring a company’s compliance program function, it is also undeniable that many compliance officers can easily fall into a rabbit hole of numbers, facts and stats. It is imperativel to shift the mindset and become more focused on the outcome of these compliance processes, rather than the output. Discuss the importance of providing meaningful progress of the compliance program and the challenges associated with providing credible evidence.

• Explore how to manage the new relationship with patients as stakeholders
• Discuss best practices for managing compliance risk in PSPs and Patient Advocacy Programs
• Assess what should these relationships look like from a transparency perspective
• Consider pre-ethic and compliance assessment in selection and hiring processes

Explore the topic of diversity, equity and inclusion in the workplace, and in the product life cycle, and discuss the key barriers that continue to exist today. Recognize the importance of environmental, social and governance practices in corporate responsibility. Join this discussion to identify key strategies and resources on how to incorporate social determinants of health equity into brand and commercial planning in a compliant manner.

• Navigate building an engaged and communicative relationship with your Commercial Field Team [Therapeutic Specialist, Sales Reps, KAM, Thought Leader Liaisons (TLLs)] and Medical Field Team [Medical Science Liaisons (MSLs), Field Medical Advisors…] to ensure positive and productive interaction with (Key Opinion Leaders) KOLs
• Differentiate between the “Commercial Field Teams” and “Medical Field Teams” roles and relationships and ensure compliant organization between Medical and Commercial
• Discover how to best optimize your relationships to gather key insights for your product development

Close out your conference experience by getting the answers to the questions you need most. Benchmark with colleagues on the daily challenges you face in your role and what you see as the biggest areas of concern moving forward.